

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescriber Name: _____ NPI #: _____
Mailing address: _____ City: _____ State: _____ ZIP: _____
7. Requester Contact Information: _____
Name: _____ Phone #: _____ Fax #: _____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: _____
11. Length of Therapy: ___ up to 30 days ___ 60 days ___ 90 days ___ 120 days ___ 180 days ___ 365 days ___ Other: _____

Clinical Information

All Prophylaxis Agents: (questions 1-5)

1. Does the beneficiary have a diagnosis of HAE I or II; AND Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test)? Yes___ No___
2. Is this request for prophylaxis of acute HAE attacks? Yes___ No___
3. Will this treatment be used in combination with other prophylactic therapies targeting C1 inhibitor (i.e., Cinryze, Haegarda, etc.) or kallikrein (i.e., Takhzyro, Orladeyo, etc.)? Yes___ No___
4. Will this treatment be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics? Yes___ No___
5. In addition, for non-preferred products, has the beneficiary tried and failed or experienced an insufficient response to at least two preferred products for the same indication or have a clinical reason that preferred products cannot be tried? Yes___ No___
List: _____

Requests for Cinryze:

6. Is the beneficiary at least 6 years of age? Yes___ No___

Requests for Haegarda:

7. Is the beneficiary at least 6 years of age? Yes___ No___

Requests for Orladeyo:

8. Is the beneficiary at least 12 years of age? Yes___ No___

Requests for Takhzyro:

9. Is the beneficiary at least 2 years of age? Yes___ No___

Renewal Criteria for ALL AGENTS:

10. Does the beneficiary continue to meet the initial criteria? Yes___ No___
11. Since starting the medication, has the beneficiary experienced significant improvement in frequency, severity and duration of attacks and has this improvement been sustained? Yes___ No___
12. Has the beneficiary experienced any unacceptable toxicity from the medication (ex: hypersensitivity reaction, thromboembolic event, etc.)? Yes___ No___

Signature of Prescriber: _____

Date: _____

***Prescriber signature mandatory**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.